It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The most advanced P. falciparum circumsporozoite protein-based malaria vaccine, RTS,S/AS01 (RTS,S), confers partial protection but with antibody titers that wane relatively rapidly, highlighting the need to elicit more potent and durable antibody responses. Here, we elucidate crystal structures, binding affinities and kinetics, and in vivo protection of eight anti-NANP antibodies derived from an RTS,S phase 2a trial and encoded by three different heavy-chain germline genes. The structures reinforce the importance of homotypic Fab-Fab interactions in protective antibodies and the overwhelmingly dominant preference for a germline-encoded aromatic residue for recognition of the NANP motif. In this study, antibody apparent affinity correlates best with protection in an in vivo mouse model, with the more potent antibodies also recognizing epitopes with repeating secondary structural motifs of type I β- and Asn pseudo 310 turns; such insights can be incorporated into design of more effective immunogens and antibodies for passive immunization.
The most advanced P. falciparum circumsporozoite protein (PfCSP)-based malaria vaccine confers partial protection. Here, Pholcharee et al. present crystal structures, binding affinities/kinetics, and in vivo protection of 8 anti-NANP antibodies to understand in vivo protection of PfCSP-targeting antibodies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)
2 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); Pfizer Inc, San Diego, USA (GRID:grid.410513.2) (ISNI:0000 0000 8800 7493)
3 Johns Hopkins Bloomberg School of Public Health, Malaria Research Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
4 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); Wondfo USA Co., Ltd, San Diego, USA (GRID:grid.214007.0)
5 Atreca Inc, South San Francisco, USA (GRID:grid.214007.0)
6 PATH’s Malaria Vaccine Initiative, Washington, USA (GRID:grid.214007.0)
7 The Scripps Research Institute, Department of Integrative Structural and Computational Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231); The Scripps Research Institute, The Skaggs Institute for Chemical Biology, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)